Antiangiogenic therapy: A novel approach to overcome tumor hypoxia

Chinese Journal of Cancer

Volumn 29, Issue 8, 2010, Pages 715-720

  Peng, Fang ^a   Chen, Ming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Antiangiogenesis; Cell hypoxia; Radiotherapy

Indexed keywords

ANGINEX; ANGIOPOIETIN 1; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; CISPLATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; MONOCLONAL ANTIBODY DC101; N ACETYLCOLCHINOL PHOSPHATE; NAVELBINE; ORANTINIB; OXYGEN; RECOMBINANT ENDOSTATIN; ROUNDABOUT RECEPTOR; SEMAPHORIN 3A; SEMAXANIB; SUNITINIB; THALIDOMIDE; TIVOZANIB; TRASTUZUMAB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANTIANGIOGENIC THERAPY; BLOOD OXYGENATION; BREAST CANCER; BREAST CARCINOMA; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; FIBROSARCOMA; GLIOMA; HUMAN; HYPOXIA; IONIZING RADIATION; LIVER CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; OXYGEN CONSUMPTION; RADIATION DOSE; RADIOSENSITIVITY; REVIEW; SARCOMA; SOLID TUMOR; SURVIVAL TIME; TUMOR HYPOXIA; TUMOR VASCULARIZATION;

EID: 79955812472     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.010.10010     Document Type: Review

References (39)

1. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction [J]. Clin Cancer Res, 2003, 9(6): 1957-1971.
2. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome [J]. Cancer Metastasis Rev, 2007, 26(2): 225-239.
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases [J]. Nature, 2000, 407(6801): 249-257.
4. Mendoza E, Burd R, Wachsberger P, et al. Normalization of tumor vasculature and improvement of radiation response by antiangiogenic agents [M]. Humana Press Inc, 2008: 311-321.
5. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer [J]. Nat Clin Pract Oncol, 2006, 3(1): 24-40.
6. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation [J]. Nature, 2008, 456(7223): 809-813.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J]. N Engl J Med, 2004, 350(23): 2335-2342.
8. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study [J]. J Clin Oncol, 2009, 27(18): 3020-3026.
9. Sun Y, Wang J, Liu Y, et al. Results of phase III trial of rhendostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients [J]. J Clin Oncol, 2005, 23(16): 654S.
10. Folkman J. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action [J]. Exp Cell Res, 2006, 312(5): 594-607.
11. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy [J]. Science, 2005, 307(5706): 58-62.
12. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases [J]. Cancer Cell, 2004, 6(6): 553-563.
13. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients [J]. J Clin Oncol, 2005, 23(31): 8136-8139.
14. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer [J]. Nat Med, 2004, 10(2): 145-147.
15. Dings RP, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization [J]. Clin Cancer Res, 2007, 13 (11): 3395-3402.
16. Hardee M, Eapen R, Rabbani Z, et al. Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu(+) tumors [J]. Cancer Chemother Pharmacol, 2009, 63(2): 219-228.
17. Cerniglia GJ, Pore N, Tsai JH, et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy [J]. PLoS One, 2009, 4(8): e6539.
18. Ansiaux R, Baudelet C, Jordan BF, et al. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy [J]. Cancer Res, 2006, 66(19): 9698-9704.
19. Ansiaux R, Dewever J, Gregoire V, et al. Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy [J]. Radiat Res, 2009, 172(5): 584-591.
20. Ansiaux R, Baudelet C, Jordan BF, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment [J]. Clin Cancer Res, 2005, 11(2 Pt 1): 743-750.
21. Dings RPM, Williams BW, Song CW, et al. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells [J]. Int J Cancer, 2005, 115(2): 312-319.
22. Lee CG, Heijn M, di Tomaso E, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions [J]. Cancer Res, 2000, 60(19): 5565-5570.
23. Wachsberger PR, Burd R, Marero N, et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma [J]. Clin Cancer Res, 2005, 11(2): 835-842.
24. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126 [J]. Int J Radiat Oncol Biol Phys, 2002, 53(1): 164-171.
25. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy [J]. Nat Med, 2001, 7(9): 987-989.
26. Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors [J]. Cancer Res, 2004, 64(11): 3731-3736.
27. Zhou QY, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide [J]. Clin Cancer Res, 2008, 14(5): 1540-1549.
28. Ohta M, Kawabata T, Yamamoto M, et al. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model [J]. Surg Today, 2009, 39(12): 1046-1053.
29. Taguchi E, Nakamura K, Miura T, et al. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model [J]. Cancer Sci, 2008, 99(3): 623-630.
30. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J]. Cancer Cell, 2007, 11(1): 83-95.
31. Hamzah J, Jugold M, Kiessling F, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction [J]. Nature, 2008, 453(7193): 410-414.
32. Mazzone M, Dettori D, de Leite OR, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization [J]. Cell, 2009, 136(5): 839-851.
33. Kashiwagi S, Tsukada K, Xu L, et al. Perivascular nitric oxide gradients normalize tumor vasculature [J]. Nat Med, 2008, 14(3): 255-257.
34. Jones CA, London NR, Chen HY, et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability [J]. Nat Med, 2008, 14(5): 585.
35. Hedlund EM, Hosaka K, Zhong Z, et al. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature [J]. Proc Natl Acad Sci U S A, 2009, 106 (41): 17505-17510.
36. Gan HK, Lappas M, Cao DX, et al. Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumor vascular normalization [J]. J Cell Mol Med, 2009.
37. Maione F, Molla F, Meda C, et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models [J]. J Clin Invest, 2009, 119(11): 3356-3372.
38. Falcon BL, Hashizume H, Koumoutsakos P, et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels [J]. Am J Pathol, 2009, 175(5): 2159-2170.
39. di Tomaso E, London N, Fuja D, et al. PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment [J]. PLoS One, 2009, 4(4): e5123.